Supplementary Materials for

Size: px
Start display at page:

Download "Supplementary Materials for"

Transcription

1 Supplementary Materials for Editing policy to fit the genome? R. M. Isasi,* E. Kleiderman, B. M. Knoppers *Corresponding author. Published 22 January 2016, Science 351, 337 (2016) DOI: /science.aad6778 This PDF file includes Table S1 References

2 Table S1. Compendium of normative and legislative documents regarding genomic technologies. Country Australia Document Title Prohibition of Human Cloning for Reproduction and the Regulation of Human Embryo Research Amendment Act (2006) Prohibition of Human Cloning for Reproduction Act (2002, last amendment 2008) Research Involving Human Embryos Act (2002, last amendment 2014) Therapeutic Goods Act (1989, last amendment 2015) National Health and Medical Research Council (2007, updated 2015), National Statement on Ethical Conduct in Research Involving Humans National Health and Medical Research Council (2004, updated 2007), Ethical Guidelines on the Use of Assisted Reproductive Technology in Clinical Practice and Research Belgium Act on Research on Embryos in Vitro (2003) / Loi relative à la recherche sur les embryons in vitro (2003) Brazil Biosafety Law (2005) Canada An Act Respecting Assisted Human Reproduction and Related Research [Assisted Human Reproduction Act] (2004) Tri Council Policy Statement Ethical Conduct for Research Involving Humans (1998, last amendment 2014) China Guidelines on Human Assisted Reproductive Technologies (2003) (available only in Chinese) China Food and Drug Administration (CFDA) (2003), The principle of research on human genetic therapy and quality control of formulation China s Ministry of Science and Technology, and Ministry of Health (2004), Guidelines for Research on Human Embryonic Stem Cells [Ethical Guiding Principles on Human Embryonic Stem Cell Research] Expert Committee of the Stem Cell Research of the China National Health and Family Planning Commission and the China Food and Drug Administration, Draft Document on Administrative Management on Clinical Research of Stem Cells (for public comments) available only in Chinese Ministry of Science and Technology of the People's Republic of China; of China (2003), Human stem cell embryo research ethics China available only in Chinese

3 of China; China Food and drug Administration (CFDA) (2013) Measures for stem cell clinical trial (for Trial Implementation) Measures for Lab Facility for stem cell clinical trial (for Trial Implementation) Principle of Quality Control for Stem Cell Formulation and Preclinical Study (for Trial Implementation) of China (2015), Measures for stem cell clinical application (for Trial Implementation) of China (1993), Quality control principle of clinical research on human somatic cell therapy and gene therapy available only in Chinese France Germany Bioethics Law / Loi n du 6 août 2004 relative à la bioéthique (2004, last amendment 2009) Code civil (1804, last amendment 2015) Loi n du 7 juillet 2011 relative à la bioéthique (2011) Loi n du 29 juillet 1994 relative au don et à l'utilisation des éléments et produits du corps humain, à l'assistance médicale à la procréation et au diagnostic prénatal (1994, last amendment 2000) Basic Law for the Federal Republic of Germany (1949, last amendment 2010) Embryo Protection Act (1990, last amendment 2012) Medicinal Products Act (The Drug Law) (1976, last amendment 2014) Stem Cell Act (2002, last amendment 2008) Bundesministerium für Bildung und Forschung (2011), Second Guideline Paper of the Federal Government for the Forthcoming Framework Programme for Research and Innovation Thematic Positions German Doctor s association Bundesärztekammer (BÄK) (2006), Forschungsklonen mit dem Ziel therapeutischer Anwendungen available only in German German Doctor s association Bundesärztekammer (BÄK) (2003), Stellungnahme der Zentralen Ethikkommission zur Stammzellforschung available only in German German National Ethics Council (Geschäftsselle des Nationalen Ethikrates) (2014), Stem cell research new challenges for the ban on cloning and treatment of artificially created germ cells? Ad hoc Recommendation German National Ethics Council (Geschäftsselle des Nationalen Ethikrates) (2004), Cloning for reproductive purposes and cloning for the

4 purposes of biomedical research, Opinion German Research Foundation (Deutsche Forschungsgemeinschaft) (2006), Stem Cell Research in Germany Possibilities and Perspectives available only in German German Research Foundation (Deutsche Forschungsgemeinschaft) (2003), Research with Human Embryonic Stem Cells, Positions German Research Foundation (Deutsche Forschungsgemeinschaft) (2001), Research Involving Human Stem Cells available only in German Interdisciplinary Research Group Gene Technology Report & Berlin Bradenburg Academy of Sciences and Humanities (2012), Gene Therapy in Germany. An Interdisciplinary Survey Supplement of the Interdisciplinary Research Group Gene Technology Report Summary Interdisciplinary Study Group Gene Technology Report & Berlin Bradenburg Academy of Science and Humanities (2008), Gene Therapy in Germany. An Interdisciplinary Survey Supplement of the German Gene Technology Report Summary Précis: Summary and Recommendations by the DFG on Stem Cell Research in Germany Possibilities and Perspectives (2006) available only in German India Israel Japan The Pre Natal Diagnostic Techniques (Regulation and Prevention of Misuse) Act (1994, last amendment 2003) Indian Council of Medical Research (2013), National Guidelines for Stem Cell Research Indian Council of Medical Research (2000, last amendment 2006), Ethical Guidelines for Biomedical Research on Human Participants Prohibition of Genetic Intervention (Human Cloning and Genetic Manipulation of Reproductive Cells) Law (1999, valid until May 23, 2016) Bioethics Advisory Committee of the Israel Academy of Sciences and Humanities (2001), Report of the Bioethics Advisory Committee of the Israel Academy of Sciences and Humanities: The Use of Embryonic Stem Cells for Therapeutic Research Act on Regulation of Human Cloning Techniques (Act No. 146 of 2000, last amendment 2014) Guidelines of Clinical Research Regarding Gene Therapy (2002, last amendment 2008) PFSB Director Notice 0907 No. 1 (2012) Japan Society of Human Genetics (2004), Guidelines for Genetic Testing Ministerial Notification of MEXT and MHLW (2004), Guideline for Gene Therapy Clinical Research available only in Japanese

5 Ministerial Notification of MHLW (2006), Guideline for Human Stem Cell Therapy Clinical Research available only in Japanese Mexico General Health Law (1984, last amendment 2015) [Penal Code of the Federal District of Mexico (Mexico DF)] Código Penal Distrito Federal de México (2002, last amendment 2014) [Regulation to the General Health Law on Sanitary Controls and Disposition of Human Organs, Tissues and Cadavers] Reglamento de la Ley General de Salud en Materia de Control Sanitario de la Disposición de Organos, Tejidos y Cadáveres de Seres Humanos (1985, last amendment 2014) [Regulation to the General Health Law on Health Research] Reglamento de la Ley General de Salud en Materia de Investigacion para la Salud (1987, last amendment 2014) The Netherlands Singapore Act Containing Rules Relating to the Use of Gametes and Embryos [The Embryos Act] (2002, last amendment 2009) 2013 amendment available only in Dutch Human Cloning and Other Prohibited Practices Act (2004, last amendment 2005) Bioethics Advisory Committee of Singapore (2015), Ethics Guidelines for Human Biomedical Research South Korea Bioethics and Safety Act (2013) United Kingdom Human Fertilisation and Embryology Act (1990, last amendment 2008) Human Fertilisation and Embryology (Mitochondrial Donation) Regulations (2015) Human Fertilisation and Embryology (Research Purposes) Regulations (2001) Medical Research Council (2010, last amendment 2015), HFEA Code of Practice for the Use of Human Stem Cell Lines United States Omnibus Appropriations Act (2009) [Dickey Wicker Amendment, 1996] Human Embryonic Stem Cell Research Advisory Committee (2010), Final Report of the National Academies Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to the National Academies Guidelines for Human Embryonic Stem Cell Research; National Academies of Science National Institutes of Health (2015), Statement on NIH funding of research using gene editing technologies in human embryos National Institutes of Health (2013), Guidelines for Research Involving

6 Recombinant or Synthetic Nucleic Acid Molecules National Institutes of Health (2009), Guidelines for Research Using Human Stem Cells White House Office of Science and Technology Policy (2015), A Note on Genome Editing

7 REFERENCES AND NOTES 1. J. S. LaFountaine, K. Fathe, H. D. Smyth, Int. J. Pharm. 494, 180 (2015). 2. J. A. Doudna, E. Charpentier, Science 346, (2014). 3. D. Cressey, A. Abott, H. Ledford, Nature (2015) /nature Regulation No. 536/2014 of the European Parliament and the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. (2014). 5. Australia, Prohibition of Human Cloning for Reproduction and the Regulation of Human Embryo Research Amendment Act, Act no. 172 (2006). 6. Australia, Prohibition of Human Cloning for Reproduction Act 2002 (last amended by Act no. 144) (2008). 7. R. M. Isasi, B. M. Knoppers, Hum. Reprod. 21, 2474 (2006). 8. R. M. Isasi, B. M. Knoppers, Eur. J. Health Law 13, 9 (2006). 9. Israel, Prohibition of Genetic Intervention (Human Cloning and Genetic Manipulation of Reproductive Cells) Law (1999) (last renewed) (2009). 10. United Kingdom, Human Fertilisation Act (1990) (last amended) (2008). 11. Belgium, Act on Research on Embryos in Vitro Loi du 11 Mai Relative a la Recherché sur les Embryons in Vitro (2003). 12. France, Bioethics Law/Loi No du 6 août 2004 relative à la bioéthique (last amended) (2009) 13. France, Code Civil (1804) re the Bioethics Law (last amended) (2015). 14. D. Baltimore et al., Science 348, 36 (2015). 15. E. Lanphier, F. Urnov, S. E. Haecker, M. Werner, J. Smolenski, Nature 519, 410 (2015). 16. Organizing Committee for the International Summit on Human Gene Editing, International Summit Statement (December, 2015); A. L. Caplan, B. Parent, M. Shen, C. Plunkett, EMBO Rep. 16, 1421 (2015). 18. J. Sugarman, EMBO Rep. 16, 879 (2015). 19. B. M. Knoppers, R. M. Isasi, Hum. Reprod. 19, 2695 (2004). 20. Penal Code of the Federal District of Mexico (Mexico DF) (2002) (last amended) (2014). 21. Bioethics Advisory Committee of Singapore, Ethics Guidelines for Human Biomedical Research, (Singapore, 2015). 22. B. M. Knoppers, S. Bordet, R. M. Isasi, Annu. Rev. Genomics Hum. Genet. 7, 201 (2006). 23. The Hinxton Group, Statement on Genome Editing Technologies and Human Germline Modification (2015);

Genome editing and bioethics

Genome editing and bioethics Genome editing and bioethics Thinking about applications in human reproduction Hugh Whittall Director, Nuffield Council on Bioethics The Nuffield Council on Bioethics Established in 1991 Funded by the

More information

Updating International Ethics Guidelines for Stem Cell Research

Updating International Ethics Guidelines for Stem Cell Research Updating International Ethics Guidelines for Stem Cell Research Jeremy Sugarman, MD, MPH, MA Harvey M. Meyerhoff Professor of Bioethics & Medicine Department of Medicine Berman Institute of Bioethics Johns

More information

The application of Genome Editing in humans

The application of Genome Editing in humans 1 The application of Genome Editing in humans A position paper of FEAM - the Federation of European Academies of Medicine With the financial support of the Interacademy Partnership for Health 2 Rapid advances

More information

Recommendation. Genome Editing Technology in Medical Sciences and Clinical Applications in Japan. September 27, 2017 Science Council of Japan

Recommendation. Genome Editing Technology in Medical Sciences and Clinical Applications in Japan. September 27, 2017 Science Council of Japan Recommendation Genome Editing Technology in Medical Sciences and Clinical Applications in Japan September 27, 2017 Science Council of Japan The original was written in Japanese and SCJ provides English

More information

Thoughts on Gene Editing Francis Collins, M.D. U.S. National Academies Human Gene Editing Committee July 12, 2016

Thoughts on Gene Editing Francis Collins, M.D. U.S. National Academies Human Gene Editing Committee July 12, 2016 Thoughts on Gene Editing Francis Collins, M.D. U.S. National Academies Human Gene Editing Committee July, 06 Topics for Discussion NIH Recombinant DNA Advisory Committee (RAC) process and recent discussion

More information

The role of the European Commission in protecting human participants in biomedical research

The role of the European Commission in protecting human participants in biomedical research European Group on Ethics in Science and New Technologies (EGE) Bureau of European Policy Advisers (BEPA) The role of the European Commission in protecting human participants in biomedical research Disclaimer:

More information

ANAT 2341 Embryology Lecture 18 Stem Cells

ANAT 2341 Embryology Lecture 18 Stem Cells ANAT 2341 Embryology Lecture 18 Stem Cells 29 September 2010 Dr Antonio Lee Neuromuscular & Regenera

More information

HUMAN GENOME EDITING FAQs

HUMAN GENOME EDITING FAQs HUMAN GENOME EDITING FAQs DEFINITIONS } What is a genome? } What is genome editing and how does it work? } What is the difference between somatic cell and germline genome editing? } What are the genome

More information

World Health Organization. The Bioethics, Regulation, and Future of Genomic Modification. Aya Lahlou & Kenza El Bernoussi

World Health Organization. The Bioethics, Regulation, and Future of Genomic Modification. Aya Lahlou & Kenza El Bernoussi World Health Organization The Bioethics, Regulation, and Future of Genomic Modification : Aya Lahlou & Kenza El Bernoussi Historical background This is a marvelous time for genetics, due largely to advances

More information

PrimePCR Pricing and Bulk Discounts

PrimePCR Pricing and Bulk Discounts Assay and Control Bulk Discounts 25% off 5 or more assays Primer Assay Pricing Product Catalog # Description List Price (EUR) Primer Assays (desalted) 10025636 Primer assay desalted, 200 reactions 96 10025637

More information

UCI ADMINISTRATIVE POLICIES & PROCEDURES

UCI ADMINISTRATIVE POLICIES & PROCEDURES UCI ADMINISTRATIVE POLICIES & PROCEDURES RESEARCH AND SPONSORED ACTIVITIES Human Stem Cell Research Oversight Program Section 484-1: Review of Human Stem Cell Activities Responsible Office: Office of Research

More information

Impact of MRCT after ICH E17 fully implement -Industry perspective-

Impact of MRCT after ICH E17 fully implement -Industry perspective- Impact of MRCT after ICH E17 fully implement -Industry perspective- 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1st, 2017 Chikara Kikuchi Vice-Chairperson, Drug Evaluation

More information

Cloning in human reproduction

Cloning in human reproduction (^Ш World Health Organization Organisation mondiale de la Santé FIFTIETH WORLD HEALTH ASSEMBLY Supplementary agenda item A50/30 8 May 1997 Cloning in human reproduction Cloning,biomedical technology and

More information

REPORT OF THE COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS

REPORT OF THE COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS REPORT OF THE COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS CEJA Report -A-0 Subject: Presented by: Referred to: Human and Nonhuman Hybrids Regina M. Benjamin, MD, Chair Reference Committee on Amendments to

More information

Genome Editing Technology - Principle -

Genome Editing Technology - Principle - Effective Date: 31.10.2017 Doc ID: 20290213 Version: 1.0 Status: Approved Planned Effective Date: 31-Oct-2017 00:00 CET (Server Date) Genome Editing Technology - Principle - Rationale Genome editing is

More information

PrimePCR Pricing and Bulk Discounts

PrimePCR Pricing and Bulk Discounts Assay and Control Bulk Discounts 25% off 5 or more assays Primer Assay Pricing Product Catalog # Description List Price (DKK) Primer Assays (desalted) 10025636 Primer assay desalted, 200 reactions DKK

More information

Outlook for Stem Cell Research: Emerging Legal Issues

Outlook for Stem Cell Research: Emerging Legal Issues Outlook for Stem Cell Research: Emerging Legal Issues Amy T. Campbell, JD, MBE SUNY Upstate Medical University * * * * * Rockefeller Inst. of Gov t Stem Cell Forum May 11, 2009 Session Objectives Provide

More information

Biomedical Research on Human Participants

Biomedical Research on Human Participants Ethical Guidelines for Biomedical Research on Human Participants Dr P Paul Kumaran MBBS, BA (Psychology), MPH Scientist E [Deputy Director Medical] National Institute for Research in Tuberculosis (ICMR)

More information

Country Key Organizations Legislation Regulations Guidelines

Country Key Organizations Legislation Regulations Guidelines AFRICA Botswana Ministry of Health, Research and Development Committee: http://www.moh.gov.bw/ Ministry of Health, Drug Regulatory Unit: http://www.moh.gov.bw/ Anthropological Research Act 45 (1967) Drugs

More information

Regulatory Perspectives of Japan

Regulatory Perspectives of Japan International Alliance for Biological Standardization (IABS) Challenge Toward Sound Scientific Regulation of Cell Therapy Products at Kyoto International Conference Center, Kyoto, Japan Regulatory Perspectives

More information

Stem cells for therapeutic use

Stem cells for therapeutic use Transition to an industrial scale of human stem cell production for therapeutic use by Bruno JARRY, Jean-François STOLTZ and Raymond ARDAILLOU on behalf of a working group joining Academy of Technologies

More information

STEERING COMMITTEE FOR THE UK STEM CELL BANK AND FOR THE USE OF STEM CELL LINES

STEERING COMMITTEE FOR THE UK STEM CELL BANK AND FOR THE USE OF STEM CELL LINES THIS PAGE MAY BE REMOVED BEFORE SUBMISSION STEERING COMMITTEE FOR THE UK STEM CELL BANK AND FOR THE USE OF STEM CELL LINES APPLICATION FORM TO IMPORT OR EXPORT HUMAN STEM CELL LINE(S) INTO OR OUT OF THE

More information

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations

More information

The European Research Council. CRISPR-Cas9 research in ERCEA Ethics Process. Filipa Ferraz de Oliveira ERCEA Scientific Officer

The European Research Council. CRISPR-Cas9 research in ERCEA Ethics Process. Filipa Ferraz de Oliveira ERCEA Scientific Officer The European Research Council CRISPR-Cas9 research in ERCEA Ethics Process Filipa Ferraz de Oliveira ERCEA Scientific Officer Fostering Responsible Research With CRISPR-Cas9, Paris, March 2016 1 CRISPR-Cas9

More information

Scientific Advice Mechanism. Scoping paper: New techniques in agricultural biotechnology

Scientific Advice Mechanism. Scoping paper: New techniques in agricultural biotechnology Scientific Advice Mechanism Scoping paper: New techniques in agricultural biotechnology 25 November, 2016 Policy context New techniques in agricultural biotechnology During the past decade a number of

More information

Professor Martin Pera. University of Melbourne Melbourne

Professor Martin Pera. University of Melbourne Melbourne Professor Martin Pera University of Melbourne Melbourne Human Pluripotent Stem Cells: The Future is Now Martin Pera University of Southern California University of Melbourne Walter and Eliza Hall Institute

More information

The University of Connecticut

The University of Connecticut The University of Connecticut Human Stem Cell Compliance Tutorial for human embryonic stem cell research and research using human induced pluripotent cells 1 Stem Cell Research is conducted both at the

More information

PrimePCR Pricing and Bulk Discounts

PrimePCR Pricing and Bulk Discounts Assay and Control Bulk Discounts 25% off 5 or more assays Primer Assay Pricing Product Catalog # Description List Price (CHF) Primer Assays (desalted) 10025636 Primer assay desalted, 200 reactions CHF

More information

Stem Cells: Ethics and Oversight May 24, Sidney H. Golub, Ph.D. Interim Director Sue & Bill Gross Stem Cell Research Center

Stem Cells: Ethics and Oversight May 24, Sidney H. Golub, Ph.D. Interim Director Sue & Bill Gross Stem Cell Research Center Stem Cells: Ethics and Oversight May 24, 2017 Sidney H. Golub, Ph.D. Interim Director Sue & Bill Gross Stem Cell Research Center Nobel Laureates 2012 John Gurdon Shinya Yamanaka Pluripotent Stem Cell PLURIPOTENT

More information

Agenzia Italiana del Farmaco

Agenzia Italiana del Farmaco Agenzia Italiana del Farmaco European Regulation on Advanced Therapies Cristina Pintus Head of European Relations Unit and Coordinator of the Advanced Therapy Project Italian Medicines Agency Proposal

More information

Activities of the Korean Association of the Institutions Review Boards (KAIRB) in the year of Korea

Activities of the Korean Association of the Institutions Review Boards (KAIRB) in the year of Korea Activities of the Korean Association of the Institutions Review Boards (KAIRB) in the year of 2002-2003 Korea October 18, 2003 Ock-Joo Kim, M.D., Ph.D. General Secretary of KAIRB (Seoul, Korea) I. Foundation

More information

ANAT 3231 Cell Biology Lecture 21 Stem Cells

ANAT 3231 Cell Biology Lecture 21 Stem Cells ANAT 3231 Cell Biology Lecture 21 Stem Cells Outline What are Stem Cells? Totipotency - Pluripotency - Multipotency What are different sources of Stem Cells? Embryonic vs Adult Pros and Cons for each type

More information

Workgroup on the Implications of Genome Editing. Douglas Mortlock Kelly Ormond On behalf of the workgroup

Workgroup on the Implications of Genome Editing. Douglas Mortlock Kelly Ormond On behalf of the workgroup Workgroup on the Implications of Genome Editing Douglas Mortlock Kelly Ormond On behalf of the workgroup Workgroup membership (to date) Douglas Mortlock Larry Brody TJ Cradick Beverly Davidson Kiran Musunuru

More information

Stem Cell Research: Identifying emerging high priority policy issues

Stem Cell Research: Identifying emerging high priority policy issues The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November

More information

Stem Cell Principle -

Stem Cell Principle - Effective Date: 31.10.2017 Doc ID: 20290214 Version: 1.0 Status: Approved Planned Effective Date: 31-Oct-2017 00:00 CET (Server Date) Stem Cell Principle - Rationale Research on human stem cells and their

More information

This document is a preview generated by EVS

This document is a preview generated by EVS TECHNICAL SPECIFICATION SPÉCIFICATION TECHNIQUE TECHNISCHE SPEZIFIKATION CEN/TS 16827-2 August 2015 ICS 11.100.10 English Version Molecular in vitro diagnostic examinations - Specifications for pre-examination

More information

Act ensuring protection of embryos in connection with the importation and utilization of human embryonic stem cells

Act ensuring protection of embryos in connection with the importation and utilization of human embryonic stem cells Act ensuring protection of embryos in connection with the importation and utilization of human embryonic stem cells Stem Cell Act (Stammzellgesetz StZG) of 28 June 2002 (amended by the Act amending the

More information

US FDA and International Regulatory Efforts in Cellular and Gene Therapies

US FDA and International Regulatory Efforts in Cellular and Gene Therapies US FDA and International Regulatory Efforts in Cellular and Gene Therapies ISCT Satellite Global Regulatory Perspectives Workshop January 27, 2013 Kimberly Benton, Ph.D. Deputy Director, Division of Cellular

More information

COUNCIL OF THE EUROPEAN UNION. Brussels, 19 July 2005 (20.07) (OR. fr) 11341/05 PI 18

COUNCIL OF THE EUROPEAN UNION. Brussels, 19 July 2005 (20.07) (OR. fr) 11341/05 PI 18 COUNCIL OF THE EUROPEAN UNION Brussels, 19 July 2005 (20.07) (OR. fr) 11341/05 PI 18 COVER NOTE from: Secretary-General of the European Commission, signed by Ms Patricia BUGNOT, Director date of receipt:

More information

Ethics. Seek to determine what a person should do, or the best course of action, and provides reasons why.

Ethics. Seek to determine what a person should do, or the best course of action, and provides reasons why. Ethics in Genetics Ethics Seek to determine what a person should do, or the best course of action, and provides reasons why. Help people discuss issues that need to be decided by individuals & as members

More information

Basic Concepts and History of Genetic Engineering. Mitesh Shrestha

Basic Concepts and History of Genetic Engineering. Mitesh Shrestha Basic Concepts and History of Genetic Engineering Mitesh Shrestha Genetic Engineering AKA gene manipulation, gene cloning, recombinant DNA technology, genetic modification, and the new genetics. A technique

More information

The NYSCF Research Institute

The NYSCF Research Institute Regenerative Medicine Research Update Susan L. Solomon The NYSCF Research Institute New York Pharma Forum February 25, 2016 Regenerative Medicine Research Regenerative medicine uses laboratory grown human

More information

Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders

Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders Background Advances in genome editing, especially the CRISPR/Cas9 genome editing system, have generated tremendous

More information

What are the origins of medical practice? Humans have been involved with medical biotechnology

What are the origins of medical practice? Humans have been involved with medical biotechnology Name: Score: / Quiz 8 on Medical Biotechnology Part 1 What are the origins of medical practice? Humans have been involved with medical biotechnology A. since the cloning of the insulin gene in the 1980s

More information

Application from the World Federation of Chinese Medicine Societies for admission into official relations with WHO

Application from the World Federation of Chinese Medicine Societies for admission into official relations with WHO EXECUTIVE BOARD EB136/NGO/6 136th session 6 November 2014 Provisional agenda item 13.3 Application from the World Federation of Chinese Medicine Societies for admission into official relations with WHO

More information

Contents. Regulatory Bodies... 13

Contents. Regulatory Bodies... 13 Contents UNITED STATES... 3 Regulatory Bodies... 3 Product Classification and Regulatory Control... 3 Application Documents... 3 Quality System Requirements... 4 Product and Manufacturer s License... 4

More information

of Innovative Pharmaceuticals* and Takao Inoue 4

of Innovative Pharmaceuticals* and Takao Inoue 4 26G-ISMS44 Regulatory Science for R&D Promotion Kazuhiko Mori 1, Takao Yamori 2, Toru Kawanishi 3, 1 Ministry of Health, Labor and Welfare (MHLW), 2 Pharmaceuticals and Medical Devices Agency (PMDA), 3

More information

CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY

CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY Executive Summary Prepared for Applied Biological Technologies Initiative Economic and Workforce Development Program California

More information

The role of Bioethics in policy-making in the European Union

The role of Bioethics in policy-making in the European Union The David F. Kelly Bioethics Lectures The role of Bioethics in policy-making in the European Union M. Patrão Neves m.patrao.neves@gmail.com www.mpatraoneves.pt The different features of bioethics matter

More information

Submission of comments on 'Reflection paper on risk based quality management in clinical trials' (EMA INS/GCP/394194/2011)

Submission of comments on 'Reflection paper on risk based quality management in clinical trials' (EMA INS/GCP/394194/2011) < Berlin, 15 February 2012 > Submission of comments on 'Reflection paper on risk based quality management in clinical trials' (EMA INS/GCP/394194/2011) Comments from: Bundesärztekammer (German Medical

More information

COMMISSION OF THE EUROPEAN COMMUNITIES

COMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 29.06.2005 COM(2005) 286 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE COMMITTEE OF THE REGIONS AND THE EUROPEAN ECONOMIC

More information

Quality & Safety GLP. 44 q&more 02/14

Quality & Safety GLP. 44 q&more 02/14 Quality & Safety GLP 44 q&more 02/14 More than keeping a lab notebook GLP regulations and their new role in the approval of medicines for advanced therapies (ATMPs) Dr Katja Schellenberg, Translation Centre

More information

Review of the ATMP Regulation

Review of the ATMP Regulation Review of the ATMP Regulation Joint DIA/MHRA Workshop on ATMPs London, 18 November 2011 Dr. Christian K Schneider Committee for Advanced Therapies (CAT) European Medicines Agency (EMA), London, UK I attend

More information

This document is a preview generated by EVS

This document is a preview generated by EVS TECHNICAL SPECIFICATION SPÉCIFICATION TECHNIQUE TECHNISCHE SPEZIFIKATION CEN/TS 16945 May 2016 ICS 11.100.10 English Version Molecular in vitro diagnostic examinations - Specifications for pre-examination

More information

GENE TECHNOLOGY LEGISLATION

GENE TECHNOLOGY LEGISLATION NBTS AND AND AUSTRALIAN GENE TECHNOLOGY LEGISLATION Dr. Michael Dornbusch Office of the Gene Technology Regulator Australia Integrated Regulation of GMOs & GM Products OGTR regulates GMOs. Some overlap

More information

Biotechnology: A Laboratory Skills Course Second Edition

Biotechnology: A Laboratory Skills Course Second Edition Now Available Biotechnology: A Laboratory Skills Course Second Edition New edition Biotechnology: A Laboratory Skills Course, second edition, by J. Kirk Brown integrates concepts and hands-on laboratory

More information

This document is a preview generated by EVS

This document is a preview generated by EVS TECHNICAL SPECIFICATION SPÉCIFICATION TECHNIQUE TECHNISCHE SPEZIFIKATION CEN/TS 16835-3 October 2015 ICS 11.100.30 English Version Molecular in vitro diagnostic examinations - Specifications for pre-examination

More information

REGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID)

REGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID) REGULATION OF BIOLOGICAL PRODUCTS IN PERU Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID) CONTENTS Introduction of DIGEMID Legal Bases of Biological Products

More information

Product Catalog # Description List Price (JPY) Primer Assays (desalted)

Product Catalog # Description List Price (JPY) Primer Assays (desalted) Assays and Controls Primer Assay Pricing Primer Assays (desalted) 10025636 Primer assay desalted, 200 reactions 16,000 (Wet-lab validated human, mouse, and rat) 10025637 Primer assay desalted, 1,000 reactions

More information

Information Day Leeds, UK 27 October 2015 Treating and managing disease

Information Day Leeds, UK 27 October 2015 Treating and managing disease The societal challenge 'Health, demographic change and well-being' Work programme 2016-2017 Information Day Leeds, UK 27 October 2015 Treating and managing disease Image credit: Adam Fagen Rallying for

More information

Re: Application for importation and trial release of Roundup Ready canola line RT73.

Re: Application for importation and trial release of Roundup Ready canola line RT73. Re: Application for importation and trial release of Roundup Ready canola line RT73. With reference to Monsanto s application for importation and trial release of Roundup Ready canola RT73, reference number

More information

Research Coverage Report by Shared Research Inc.

Research Coverage Report by Shared Research Inc. 3-D MATIX / 7777 esearch eport by Shared esearch Inc. https://sharedresearch.jp This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this

More information

Interagency Secretariat on Research Ethics 350 Albert Street Ottawa, ON Canada K1A 1H5. February 25, To Whom It May Concern:

Interagency Secretariat on Research Ethics 350 Albert Street Ottawa, ON Canada K1A 1H5. February 25, To Whom It May Concern: Faculty of Medicine Interagency Secretariat on Research Ethics 350 Albert Street Ottawa, ON Canada K1A 1H5 February 25, 2010 To Whom It May Concern: During the previous consultation period, I underlined

More information

Biosafety and the NIH Guidelines

Biosafety and the NIH Guidelines Biosafety and the NIH Guidelines This section will explore: Why the NIH Guidelines are important The definition of recombinant or synthetic nucleic acid research Content of the NIH Guidelines Section III

More information

Ethics Review and the FP7 Ethics Framework

Ethics Review and the FP7 Ethics Framework Ethics Review and the FP7 Ethics Framework Isidoros Karatzas Head of the Ethics Review Sector European Commission 1 Compliance of researchers with ethical standards A case-to-case review of all research

More information

The Brazilian regulatory system for cell therapy products

The Brazilian regulatory system for cell therapy products The Brazilian regulatory system for cell therapy products Brasília 23 de outubro de 2018 Gerência de Sangue, Tecidos, Células e Órgãos GSTCO Diretoria de Autorização e Registros Sanitários - Diare Agência

More information

THE GLOBAL MARKET FOR STEM CELLS

THE GLOBAL MARKET FOR STEM CELLS THE GLOBAL MARKET FOR STEM CELLS BIO035F May 2016 Paul Evers Project Analyst ISBN: 1-62296-292-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the USA),

More information

Opinion: Scientists discuss when "gene editing" technology should be used

Opinion: Scientists discuss when gene editing technology should be used Opinion: Scientists discuss when "gene editing" technology should be used By Scientific American, adapted by Newsela staff on 12.09.15 Word Count 921 Emmanuelle Charpentier of the Max Planck Institute

More information

Animal Cloning and Nanotechnology - food-related regulatory aspects from an EU perspective

Animal Cloning and Nanotechnology - food-related regulatory aspects from an EU perspective Animal Cloning and Nanotechnology - food-related regulatory aspects from an EU perspective Kai-Uwe Sprenger Philippe Martin Wolf Maier DG Health and Consumer Protection http://ec.europa.eu/comm/food/animal/index_en.htm

More information

Genome Editing Introduction 1 Genome editing or gene editing is used to describe a number of recently developed technologies that can amend human,

Genome Editing Introduction 1 Genome editing or gene editing is used to describe a number of recently developed technologies that can amend human, Genome Editing Introduction 1 Genome editing or gene editing is used to describe a number of recently developed technologies that can amend human, non-human animal or plant DNA. The techniques can be applied

More information

Social and Ethical Issues in Systems Biology. HW: pg 120 #1-5, 9-11, 14

Social and Ethical Issues in Systems Biology. HW: pg 120 #1-5, 9-11, 14 Social and Ethical Issues in Systems Biology HW: pg 120 #1-5, 9-11, 14 Transplanting Organs Organ transplantation involves the removal of an organ from donor body and placement in a recipient body, wherein

More information

Overview of the NIH Guidelines for Research Involving Recombinant DNA Molecules

Overview of the NIH Guidelines for Research Involving Recombinant DNA Molecules Overview of the NIH Guidelines for Research Involving Recombinant DNA Molecules A scientifically responsive document that will continue to evolve Has undergone multiple revisions since 1976 Latest version

More information

Recombinant DNA and Research with Animals

Recombinant DNA and Research with Animals Recombinant DNA and Research with Animals Recombinant DNA and Research with Animals Jan V. Parker-Thornburg, Ph.D. Director, Transgenic Animal Core Facility MD Anderson Cancer Center Stephen H. Hughes,

More information

Stem Cell. Running head: STEM CELL RESEARCH. Stem Cell Research. Student s Name. University Affiliation

Stem Cell. Running head: STEM CELL RESEARCH. Stem Cell Research. Student s Name. University Affiliation 1 Running head: STEM CELL RESEARCH Stem Cell Research Student s Name University Affiliation 2 Stem Cell Research Stem cell research is the subject of many current researches and studies all over the world.

More information

What are clones? Genetically identical copies

What are clones? Genetically identical copies Cloning What are clones? Genetically identical copies The possibility of human cloning was raised when Scottish scientists at Roslin Institute created the much-celebrated sheep "Dolly" Cloning Cloning

More information

Country Key Organizations Legislation Regulations Guidelines

Country Key Organizations Legislation Regulations Guidelines ASIA/PACIFIC/MIDDLE EAST Australia 1. National Health and Medical Research Council (NHMRC): http://www.nhmrc.gov.au/ 2. Australian Research Council (ARC): http://www.arc.gov.au/ 3. Universities Australia

More information

INTRODUCTION KEY WORDS CFMUNESCO 2018

INTRODUCTION KEY WORDS CFMUNESCO 2018 CFMUNESCO 2018 COMMITTEE: World Health Organisation TOPIC: The Question of defining a Regulation for the use of Stem Cells CHAIRS: Cristina Lauretig, Lucrezia Rosina INTRODUCTION There is at present a

More information

Current GMP Inspection of PMDA. Shingou SAKURAI, Ph.D Office of Compliance and Standards Pharmaceuticals and Medical Devices Agency(PMDA), JAPAN

Current GMP Inspection of PMDA. Shingou SAKURAI, Ph.D Office of Compliance and Standards Pharmaceuticals and Medical Devices Agency(PMDA), JAPAN Current GMP Inspection of PMDA Shingou SAKURAI, Ph.D Office of Compliance and Standards Pharmaceuticals and Medical Devices Agency(PMDA), JAPAN GMP Inspection related Organizations in Japan Organizations

More information

10728/4/16 REV 4 ADD 1 psc 1 DRI

10728/4/16 REV 4 ADD 1 psc 1 DRI Council of the European Union Brussels, 7 March 2017 (OR. en) Interinstitutional File: 2012/0266 (COD) 10728/4/16 REV 4 ADD 1 STATEMT OF THE COUNCIL'S REASONS Subject: PHARM 43 SAN 284 MI 478 COMPET 402

More information

New Direction of Japanese Regulations on MD/IVD. - Japan Update -

New Direction of Japanese Regulations on MD/IVD. - Japan Update - New Direction of Japanese Regulations on MD/IVD - Japan Update - Topics Collaboration plan to accelerate review of MDs Revision of Pharmaceutical Affairs Law (PAL); Implementation of PMD Act. 2 Collaboration

More information

Trend analysis Biotechnology 2016

Trend analysis Biotechnology 2016 Trend analysis Biotechnology 2016 Summary april 2016 1 Trendanalyse Biotechnologie 2016 - Regelgeving ontregeld Scientific advances in biotechnology have taken off in recent years. New techniques and applications

More information

Conditional Early Approval System for Innovative Medical Device Products (Fast-Break Scheme)

Conditional Early Approval System for Innovative Medical Device Products (Fast-Break Scheme) PSEHB Notification No. 0731-1 July 31, 2017 To: Prefectural Governors Director-General of the Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare (Official seal

More information

3. Human Biomedical Research. Defining Human Biomedical Research

3. Human Biomedical Research. Defining Human Biomedical Research PART B: SECTION III: HUMAN BIOMEDICAL RESEARCH HUMAN BIOMEDICAL RESEARCH 3. Human Biomedical Research Defining Human Biomedical Research 3.1. In this section, we consider what kinds of human biomedical

More information

Current situation on nonclinical safety evaluation of regenerative medical products in Japan

Current situation on nonclinical safety evaluation of regenerative medical products in Japan Current situation on nonclinical safety evaluation of regenerative medical products in Japan Takuya Nishimura Office of Cellular and Tissue based Products PMDA Disclaimers The views expressed in this presentation

More information

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004 Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive

More information

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member

More information

Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer

Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study Catherine Mathis Director of Regulatory Affairs transgene 1 Disclaimer The views and opinions expressed in the following

More information

Central Issues in Biotechnology and Ethics in the 21th Century

Central Issues in Biotechnology and Ethics in the 21th Century Central Issues in Biotechnology and Ethics in the 21th Century Professor Dr. Herbert Gottweis Life Science Governance Research Platform/ Department of Political Science University of Vienna Presentation

More information

Regulatory Newsletter January - March 2014

Regulatory Newsletter January - March 2014 Regulatory Newsletter January - March 2014 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree Deliver motto!

More information

CURRENT CHALLENGES IN INTELLECTUAL PROPERTY RIGHTS AND PHARMACEUTICALS WIPO INTERNATIONAL SEMINAR

CURRENT CHALLENGES IN INTELLECTUAL PROPERTY RIGHTS AND PHARMACEUTICALS WIPO INTERNATIONAL SEMINAR CURRENT CHALLENGES IN INTELLECTUAL PROPERTY RIGHTS AND PHARMACEUTICALS WIPO INTERNATIONAL SEMINAR ZLATA SLADIĆ, M. Sc. in Biomedicine Banska Bystrica Republic of Slovakia, May 2 and 3, 2007 INTELLECTUAL

More information

The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme

The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme 18/10/2016 The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme Chinese & European Pharmacopoeias Workshop 17 October 2016

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) <DRAFT>

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) <DRAFT> European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 17 November 2005 Doc. Ref. EMEA/273974/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) NOTE

More information

Discover the Importance of Third Party Quality Control

Discover the Importance of Third Party Quality Control Bio-Rad Laboratories Q U A L I T Y C O N T R O L Discover the Importance of Third Party Quality Control Introduce Your Laboratory to an Independent Assessment Bio-Rad Laboratories Q U A L I T Y C O N T

More information

REPORT OF THE IBC WORKING GROUP ON HUMAN CLONING AND INTERNATIONAL GOVERNANCE

REPORT OF THE IBC WORKING GROUP ON HUMAN CLONING AND INTERNATIONAL GOVERNANCE Distribution: limited SHS/EST/CIB-17/10/CONF.501/4 REV Paris, 7 October 2010 Original: English REPORT OF THE IBC WORKING GROUP ON HUMAN CLONING AND INTERNATIONAL GOVERNANCE This report has been drawn up

More information

Propositions on Genetic Engineering: Assignment 3/13 Integrated Science 4 Redwood High School Name: Per:

Propositions on Genetic Engineering: Assignment 3/13 Integrated Science 4 Redwood High School Name: Per: Propositions on Genetic Engineering: Assignment 3/13 Integrated Science 4 Redwood High School Name: Per: n Introduction Since the early 1950 s, advances in the field of genetics have reshaped the science

More information

Assessing ethical complications concerning fetal genetic modification

Assessing ethical complications concerning fetal genetic modification Assessing ethical complications concerning fetal genetic modification In this Council, delegates will discuss the ethical implications surrounding genetic modifications on human embryos or fetuses. While

More information

QUESTION 114. Biotechnology

QUESTION 114. Biotechnology QUESTION 114 Yearbook 1994/II, pages 396-397 Executive Committee of Copenhagen, June 12-18, 1994 Q114 Question Q114 Resolution AIPPI taking into account recent developments in the fields of science and

More information

Clinical trial applications in the EU and US

Clinical trial applications in the EU and US Clinical trial applications in the EU and US Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Symposium Strasbourg 17-18 March 2005 Overview of the presentation

More information

Yoji SATO, Ph.D. Head, Division of Cellular & Gene Therapy Products National Institute of Health Sciences, Tokyo, Japan

Yoji SATO, Ph.D. Head, Division of Cellular & Gene Therapy Products National Institute of Health Sciences, Tokyo, Japan NIHS Since 1874 Yoji SATO, Ph.D. Head, Division of Cellular & Gene Therapy Products National Institute of Health Sciences, Tokyo, Japan October 21, 2013 DISCLAIMER: The views and opinions expressed in

More information

Cellular Therapy Products & NDC vs. ISBT128 Coding/Labeling

Cellular Therapy Products & NDC vs. ISBT128 Coding/Labeling Cellular Therapy Products & NDC vs. ISBT128 Coding/Labeling William E. Janssen, Ph.D. Director, Cell Therapies Facility Moffitt Cancer Center Tampa, Florida What is ISBT 128? Information standard for blood,

More information